title: Low level of interleukin 10 synthesis during liver allograft rejection.
abstract: Interleukin 10 (IL-10) is a macrophage and T-cell-derived cytokine with potent immunosuppressive properties. To assess its role in liver allograft rejection, we evaluated the plasma level and in situ production of IL-10 after liver transplantation and designed in vitro studies to asses the effects of IL-10 on the allogeneic response. Normal controls and liver transplant recipients with acute rejection, chronic rejection, other complications (recurrent hepatitis C, biliary complications), or no complications were evaluated. The plasma IL-10 level was measured by an immunoenzymatic technique. IL-10 expression in the liver was detected on frozen liver biopsies by in situ hybridization and immunohistochemistry. Plasma IL-10 levels were not elevated during acute or chronic rejection, when compared with liver recipients with uncomplicated transplants. IL-10 mRNA and protein expressions in the liver graft were restricted to rare scattered sinusoidal cells of transplant recipients with acute or chronic rejection, as well as in those with no complications. In mixed lymphocyte cultures performed with peripheral blood mononuclear cells (PBMC) from normal subjects, IL-10 decreased the cell proliferation in a dose-dependent manner, and this immunosuppression was synergistic with that of cyclosporine or FK506. These findings indicate that IL-10 production is low during allograft rejection. Thus, IL-10 therapy in association with cyclosporine or FK506 might be proposed after liver transplantation.
authors.affiliation: Laboratoire d'Immunologie et de Biologie Cellulaire, Faculté de Médecine Cochin-Port-Royal, Université Paris V, France.
authors.forename: F
authors.initials: F
authors.lastname: Conti
authors.forename: M L
authors.initials: ML
authors.lastname: Boulland
authors.forename: K
authors.initials: K
authors.lastname: Leroy-Viard
authors.forename: C
authors.initials: C
authors.lastname: Chereau
authors.forename: B
authors.initials: B
authors.lastname: Dousset
authors.forename: O
authors.initials: O
authors.lastname: Soubrane
authors.forename: B
authors.initials: B
authors.lastname: Weill
authors.forename: Y
authors.initials: Y
authors.lastname: Calmus
mesh_terms: D000208:Acute Disease; D001379:Azathioprine / Q000627:therapeutic use; D002478:Cells, Cultured; D002908:Chronic Disease; D016572:Cyclosporine / Q000494:pharmacology; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D016559:Tacrolimus / Q000494:pharmacology; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016753:Interleukin-10; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus; D008775:Methylprednisolone